Diuretics

Side Effects of Drugs Annual

Volumn 31, Issue C, 2009, Pages 371-381

  Aronson, J K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954641164     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(09)03121-3     Document Type: Article

References (95)

1. Inoue K, Wada SA, Wakakura M, Inoue J, Tomita G. Switching from dorzolamide to brinzolamide: effect on intraocular pressure and patient comfort. Jpn J Ophthalmol 2006;50(1):68-9.
2. Hillenbrand P, Pahari AK, Soon Y, Subedi D, Bajracharya R, Gurung P, Lal BK, Marahatta R, Pradhan S, Rai D, Sharma S. Birmingham Medical Research Expeditionary Society. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial. Wilderness Environ Med 2006;17(2):87-93.
3. López-Menchero R, Albero MD, Barrachina MD, Alvarez L. Fracaso renal agudo anúrico secundario a tratamiento con acetazolamida. [Anuric acute renal failure due to acetazola mide.] Nefrologia 2006;26(6):755-6.
4. Franks W. Brinzolamide Study Group. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 2006;22(9):1643-9.
5. Reis R, Queiroz CF, Santos LC, Avila MP, Magacho L. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther 2006;28(4):552-9.
6. Parmaksiz S, Yüksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol 2006;16(1):73-80.
7. Cac-a I, Simsek H, Unlü K, Ari S, Keklikc-i U. A comparison of latanoprost monotherapy with a combination therapy of timolol/dorzolamide in patients with primary open-angle glaucoma. Ann Ophthalmol (Skokie) 2006;38 (2):111-5.
8. Suzuki Jr ER, Franklin LM, da Silva LJ, Figueiredo CR, Netto JA, Batista WD. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 2006;22(9): 1799-805.
9. Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol 2006;61(1):87-95.
10. Chow KM, Szeto CC, Kwan BC, Li PK. Influence of climate on the incidence of thiazide-induced hyponatraemia. Int J Clin Pract 2007;61(3):449-52.
11. Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006;81(6):796-806.
12. Saglid U, Andersen V, Andreasen PB. Glucose tolerance and insulin responsiveness in experimental potassium depletion. Acta Med Scand 1961;3:243-51.
13. Rapoport MI, Hurd HF. Thiazide-induced glucose intolerance treated with potassium. Arch Intern Med 1964;113:405-8.
14. Gordon P, Sherman BM, Simopoulos AP. Glucose intolerance with hypokalemia: failure of short-term potassium depletion in normal subjects to reproduce the glucose and insulin abnormalities of clinical hypokalemia. Diabetes 1973;22:544-51.
15. Rowe JW, Tobin JD, Rosa RM, Andres R. Effects of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 1980;29:498-502.
16. Cutler JA. Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key? Hypertension 2006;48(2):198-200.
17. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48(2): 219-24.
18. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004;27: 247-55.
19. Wright Jr JT, Dunn JK, Cutler JA, et al. ALLHAT Collaborative Research Group Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005;293:1595-608.
20. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson JALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006;166(20):2191-201.
21. Odvina CV, Mason RP, Pak CY. Prevention of thiazide-induced hypokalemia without magnesium depletion by potassium-magnesium-citrate. Am J Ther 2006;13(2): 101-8.
22. Pfab F, Athanasiadis GI, Kollmar A, Ring J, Ollert M. Lichenoid drug eruption due to an antihypertonic drug containing irbesartan and hydrochlorothiazide. Allergy 2006; 61(6):786-7.
23. Lee-Chiong Jr T, Matthay RA, Lee-Chiong Jr T, Matthay RA. Drug-induced pulmonary edema and acute respiratory distress syndrome. Clin Chest Med 2004;25(1): 95-104.
24. Steinberg AD. Pulmonary edema fol lowing ingestion of hydrochlorothiazide. JAMA 1968;204(9):825-7.
25. Goetschalckx K, Ceuppens J, Van Mieghem W. Hydrochlorothiazide-associated noncardiogenic pulmonary oedema and shock: a case report and review of the literature. Acta Cardiol 2007;62(2):215-20.
26. Parfrey NA, Herlong HF. Pulmonary oedema after hydrochlorothiazide. Br Med J 1984;288(6434):1880.
27. Garcia MJ, Kidwai Z, Rosa J, Cooper EB. Thiazide-induced pulmonary edema: a case report. Conn Med 1992;56(4):185-6.
28. Shieh CM, Chen CH, Tao CW, Tsai JJ, Perng RP. Hydrochlorothiazide-induced pulmonary edema: a case report and literature review. Zhonghua Yi Xue Za Zhi (Taipei) 1992;50(6):495-9.
29. Frierson JH, Marvel SL, Thomas GM. Hydrochlorothiazide-induced pulmonary edema with severe acute myocardial dysfunction. Clin Cardiol 1995;18(2):112-4.
30. Hovenga S, Koenders ME, van der Werf TS, Moshage H, Zijlstra JG. Methaemoglobinaemia after inhalation of nitric oxide for treatment of hydrochlorothiazide-induced pulmonary oedema. Lancet 1996;348(9033): 1035-6.
31. Marín P. Edema pulmonar agudo asociado a hidroclorotiazida. [Pulmonary edema associated with the ingestion of hydrochlorothiazide.] Rev Med Chil 1996;124(12): 1492-5.
32. Saldana A, Jalil J, Gaete P, Fajuri A, Castro P, Godoy I, Corbalán R. Edema pulmonar no-cardiogenico relacionado con la hidroclorotiazida. [Noncardiogenic pulmonary edema associated with hydrochlorothiazide use.] Rev Med Chil 1996;124(6):720-4.
33. Mas A, Jordana R, Valles J, Cervantes M. Recurrent hydrochlorothiazide-induced pulmonary edema. Intensive Care Med 1998;24(4):363-5.
34. Bernal C, Patarca R. Hydrochlorothiazide-induced pulmonary edema and associated immunologic changes. Ann Pharmacother 1999;33(2):172-4.
35. d'Aloia A, Fiorina C, Vizzardi E, Faggiano P, Dei Cas L. Episodi ricorrenti di edema pol-monare acuto non cardiogeno indotti dall'as-sunzione di idroclorotiazide. [Recurrent episodes of acute non-cardiogenic pulmonary edema caused by ingesting hydrochlorothiazide.] Ital Heart J Suppl 2001;2(8):904-7.
36. Gamboa PM, Achotegui V, Irigoyen J, Perez-Asenjo J, Merino J, Sanz ML. Hydrochlorotiazide-induced acute non-cardiogenic pulmonary edema. J Investig Allergol Clin Immunol 2005;15(4):299-301.
37. Knowles SR, Wong GA, Rahim SA, Binkley K, Phillips EJ, Shear NH. Hydrochlorothiazide-induced noncardiogenic pulmonary edema: an underrecognized yet serious adverse drug reaction. Pharmacotherapy 2005;25(9):1258-65.
38. Vereda A, Cárdaba B, Quirce S, de las Heras M, Cuesta J, Sastre J. Immunological studies in a case of hydrochlorothiazideinduced pulmonary edema. J Investig Allergol Clin Immunol 2005;15(4):297-8.
39. Solar M, Ceral J, Kvasnicka J. Hydrochlorothiazide induced pulmonary edema-a rare side effect of common diuretic drug. Int J Cardiol 2006;112(2):251-2.
40. Andresen M, González A, Espino A, Mercado M, Regueira T, Dougnac A. Edema pulmonar agudo por uso de tiazidas, ¿existe falla cardiaca?: Comunicacion de un caso. [Thiazide-induced acute pulmonary edema: report of a case.] Rev Med Chil 2007;135(4):496-500.
41. Beaudry C, Laplante L. Severe allergic pneumonitis from hydrochlorothiazide. Ann Intern Med 1973;78:251-3.
42. Kaufman A, Montilla E, Helfgott M, Fiorelli R, Mueller H. Pneumonitis and hydrochlorothiazide. Ann Intern Med 1973; 79(2):283.
43. Farrell Jr TC, Schillaci RF. Hydrochlor-othiazide-induced pulmonary edema mimicking metastatic carcinoma of the breast. Cardiopulm Med 1976;15:16-7.
44. Bell RT, Lippmann M. Hydrochlorothiazide-induced pulmonary edema. Arch Intern Med 1979;139:817-9.
45. Gould L, Reddy CVR, Zen B, Singh BK. Life threatening reactions to thiazides. N Y State J Med 1980;80(13):1975-6.
46. Carlson RW, Schaeffer Jr RC, Puri VK, Brennan AP, Weil MH. Hypovolemia and permeability pulmonary edema associated with anaphylaxis. Crit Care Med 1981;9(12): 883-5.
47. Dorn MR, Walker BK. Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy. Chest 1981;79(4):482-3.
48. Piper C, Wallem D, Wesche D, Brattig N, Diao GJ, Berg PA. Lungenodum nach Eurnahme von Hydrochlorothiazid. [Lung edema after administration of hydrochlorothiazide. A rare and life-threatening side effect.] Dtsch Med Wochenschr 1983;108 (39): 1480-3.
49. Prupas HM, Brown D. Acute idiosyncratic reaction to hydrochlorothiazide ingestion. West J Med 1983;138(1):101-2.
50. Wagner AC. Interstitial pulmonary edema due to hydrochlorothiazide: case report. Va Med 1983;110(12):715-6.
51. Levay ID. Hydrochlorothiazide-induced pulmonary edema. Drug Intell Clin Pharm 1984;18(3):238-9.
52. Napke E, Stevens DGH. Excipients and additives: hidden hazards in drug products and in product substitution. Can Med Assoc J 1984;131(12):1449-52.
53. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputabilite des éffets inattendus ou tox-iques des médicaments. Actualisation de la méthode utilisée en France. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France.] Therapie 1985;40:111-8.
54. Kounis NG, Nikolaou S, Zavras G, Siablis D. Severe acute interstitial pulmonary edema from Moduretics (amiloride plus Hydrochlorotiazide). Ann Allergy 1986;57:417-8.
55. Watrigant Y, Wallaert B, Ramon P, Gosselin B, Peng W, Tonnel AB. Pneumopathie à l'hydrochlorothiazide d'évolution subaiguë. [Subacute pneumopathy caused by hydrochlorothiazide. Cytologic study of the broncho-alveolar lavage.] Rev Mal Respir 1986;3(4):227-9.
56. Alted E, Navarro M, Cantalapiedra JA, Alvarez JA, Blasco MA, Nunez A. Non cardiogenic pulmonary edema after oral ingestion of hydrochlorothiazide. Intensive Care Med 1987;13(5):364-5.
57. Klein MD. Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion. Ann Emerg Med 1987;16(8):901-3.
58. Caduff F, Gloor HJ. Hydrochlorothiazid-induziertes Lungenodem mit Schock. [Hydrochlorothiazide-induced lung edema with shock.] Schweiz Med Wochenschr 1988;118(4):139-42.
59. Anderson TJ, Berthiaume Y, Matheson D, Boiteau P. Hydrochlorothiazide-associated pulmonary edema. Chest 1989;96(3):695-7.
60. Grace AA, Morgan AD, Strickland NH. Hydrochlorothiazide causing unexplained pulmonary oedema. Br J Clin Pract 1989; 43(2):79-81.
61. Pedrol E, Bosch X, Sajche JC, Font J. Edema pulmonar no cardiogenico inducido por hidroclorotiacide. [Non-cardiogenic pulmonary edema induced by hydrochlorothiazide.] Rev Clin Esp 1989;185(6):94-5.
62. Hoegholm A, Rasmussen SW, Kristensen KS. Pulmonary oedema with shock induced by hydrochlorothiazide: a rare side effect mimicking myocardial infarction. Br Heart J 1990;63(3):186.
63. Kavaru MS, Ahmad M, Amirthalingam KN. Hydrochlorothiazide-induced acute pulmonary edema. Cleve Clin J Med 1990; 57(2):181-4.
64. Reed CR, Glauser FL. Drug-induced non-cardiogenic pulmonary edema. Chest 1991; 100(4):1120-4.
65. Barroso MS, Solé T, Moitinho E, Pedrol E. Hidroclorotiazida y edema agudo de pulmon no cardiogenico: aporacion de un nuevo caso. [Hydrochlorothiazide and non-cardiogenic pulmonary acute edema: presentation of a new case.] An Med Int 1993;10(4):207.
66. Leser C, Bolliger CT, Winnewisser J, Burkart F, Perruchoud AP. Pulmonary oedema and hypotension induced by hydrochlorothiazide. Monaldi Arch Chest Dis 1994;49(4):308-10.
67. Fine SR, Lodha A, Zoneraich S, Mollura JL. Hydrochlorothiazide-induced acute pulmonary edema. Ann Pharmacother 1995; 29(7-8):701-3.
68. Blaauwwiekel EE, Zijlstra JG. Acuut longoedeem door hydrochloorthiazide. [Acute pulmonary edema caused by hydrochlorothiazide.] Ned Tijdschr Geneeskd 1996; 140(44):2193-5.
69. Young CC, Kyle JL, Young RT. Acute pulmonary edema caused by ingestion of hydrochlorothiazide. Wis Med J 1997;96(3): 38-9.
70. Daszenies C. Edema pulmonar agudo aso-ciado a hidroclorotiazida. Experiencia en un hospital rural de Chiloé. [Acute pulmonary edema associated with hydrochlorothiazide. Experience in a rural hospital of Chiloé, Chile.] Rev Med Chil 1998;126(2):227-8.
71. Almoosa KF. Hydrochlorothiazide-induced pulmonary edema. South Med J 1999; 92(11):1100-2.
72. Chittivelu S. Comment: hydrochlorothiazide-induced pulmonary edema and associated immunologic changes. Ann Pharmacother 1999;33(9):1010-1.
73. Torné Cachot J, Penarrubia María MT, Moner Coromina L. Edema agudo de pulmon no cardiogenico y leucopenia recur-rente por hidroclorotiazida. [Non-cardiogenic acute pulmonary edema and recurrent leu-kopenia caused by hydrochlorothiazide.] Rev Clin Esp 2001;201(2):107-8.
74. Jara Chinarro B, de Miguel Díez J, García Satue JL, Juretschke Moragues MA, Serrano Iglesias JA. Edema agudo de pulmon no cardiogenico secundario a hidroclorotiazida. [Acute non-cardiogenic pulmonary edema secondary to hydrochlorothiazide therapy.] Arch Bronconeumol 2003;39(2):91-3.
75. Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide. Can Med Assoc J 1991;145(1):28-34 erratum 391
76. Eisenhut M. Hydrochlorothiazide induced pulmonary oedema and alveolar epithelial ion transport. Int J Cardiol 2007;118(1): 118-9.
77. Bowden FJ. Non-cardiogenic pulmonary oedema after ingestion of chlorothiazide. BMJ 1989;298(6673):605.
78. Andrianopoulos C, Stephanou G, Demopoulos NA. Genotoxicity of hydrochlorothiazide in cultured human lymphocytes. I. Evaluation of chromosome delay and chromosome breakage. Environ Mol Mutagen 2006;47(3):169-78.
79. Vaidyanathan S, Valencia J, Kemp C, Zhao C, Yeh CM, Bizot MN, Denouel J, Dieterich HA, Dole WP. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60(11):1343-56.
80. Ali SK. Renal calculi complicating short-term furosemide therapy after congenital heart surgery. Congenit Heart Dis 2006; 1(5):251-3.
81. Davidovici BB, Naveh HP, Cagnano E, Halevy SRegiSCAR Study Group. Acute generalized exanthematous pustulosis (AGEP) following intake of furosemide. Harefuah 2006;145(7):477-9 552
82. Lee JJ, Downham 2nd TF. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol 2006;5(6):562-4.
83. Strid S, Nilsson D, Borgå O, Wemer J, Grahnén A. NXY-059 does not significantly interact with furosemide in healthy volunteers. J Clin Pharmacol 2006;46(12):1417-25.
84. Gulbis BE, Spencer AP. Efficacy and safety of a furosemide continuous infusion following cardiac surgery. Ann Pharmacother 2006;40(10):1797-803.
85. Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ 2006; 333(7563):330.
86. Dawwas MF. Spironolactone and risk of upper gastrointestinal events: association is unproved. BMJ 2006;333(7566):501.
87. Campbell E, Shonde A, Foley S. Spironolactone and risk of upper gastrointestinal events: spironolactone may not be guilty. BMJ 2006;333(7566):500.
88. Williams EM, Katholi RE, Karambelas MR. Use and side-effect profile of spironolactone in a private cardiologist's practice. Clin Cardiol 2006;29(4):149-53.
89. Karagiannis A, Tziomalos K, Kakafika A, Florentin M, Athyros VG. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrol Dial Transplant 2007;22(1):293.
90. Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004;217(1-2):27-31.
91. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
92. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341: 709-17.
93. McManus ML, Soriano SG. Rebound swelling of astroglial cells exposed to hypertonic mannitol. Anesthesiology 1998;88(6): 1586-91.
94. Palma L, Bruni G, Fiaschi AI, Mariottini A. Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon. A study on 21 patients. J Neurosurg Sci 2006;50(3):63-6.
95. Kimura S, Ogawa H, Katayama Y. Hyperkalemia caused by intravenous administration of mannitol in a patient with arteriovenous malformation: case report. No Shinkei Geka 2006;34(1):51-6.